For a patient otherwise suitable for APBI, would neoadjuvant endocrine therapy administered for extemporizing reasons (e.g., COVID diagnosis and recovery, rather than downstaging) preclude consideration of APBI?  

I have not typically treated patients with APBI if undergoing neoadjuvant therapy (chemotherapy or endocrine therapy). In theory, if endocrine therapy was a short amount of time, PBI could be considered but I have favored HWBI in these situations.